Neuromyelitis optica spectrum disorder laboratory findings
Jump to navigation
Jump to search
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder laboratory findings On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder laboratory findings |
|
FDA on Neuromyelitis optica spectrum disorder laboratory findings |
|
CDC on Neuromyelitis optica spectrum disorder laboratory findings |
|
Neuromyelitis optica spectrum disorder laboratory findings in the news |
|
Blogs on Neuromyelitis optica spectrum disorder laboratory findings |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
|
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- Laboratory evaluation of neuromyelitis optica spectrum disorder (NMOSD) centers on serum aquaporin-4 immunoglobulin G (AQP4-IgG). A positive result must accompany a compatible core clinical characteristic and exclusion of alternative diagnoses; antibody positivity alone is insufficient.[1]
- Published 2026 guidance from the Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) recommends cell-based AQP4-IgG testing and retains the 2015 diagnostic framework.[2]
Laboratory Findings
Serum aquaporin-4 immunoglobulin G
- Neuromyelitis optica spectrum disorder testing should use a validated cell-based assay (CBA).[2][3]
- Specimen: Serum is preferred; routine cerebrospinal fluid (CSF) AQP4-IgG testing does not replace serum testing.[1]
- Positive result: Supports AQP4-IgG-positive NMOSD when the clinical criteria are met.[1]
- Negative result: Does not exclude NMOSD. Antibody-negative cases require stricter diagnostic criteria and careful exclusion of other causes.[1]
- Unexpected or low-positive result: Confirm with another CBA or a subsequent serum sample, particularly when the presentation is atypical.[1][4]
Specimen timing, repeat testing, and reporting
- Neuromyelitis optica spectrum disorder antibody testing should preferably precede immunotherapy; persistent suspicion after a negative result warrants repeat testing, ideally during an attack or a treatment-free interval when clinically appropriate.[4]
- Record the specimen, sampling date, assay type, laboratory, result, available titer and cutoff, and attack/remission and treatment status.[4]
- Waiting for antibody confirmation must not delay urgent care for a suspected attack.[5]
Serum myelin oligodendrocyte glycoprotein immunoglobulin G
- Neuromyelitis optica spectrum disorder assessment includes consideration of myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG), especially in AQP4-IgG-negative presentations.[2]
- MOG-IgG positivity with an appropriate presentation supports myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a distinct disorder, rather than confirming NMOSD.[6]
- Use a CBA displaying conformationally intact, full-length human MOG. Select testing according to the clinical presentation; indiscriminate screening increases the risk of misleading positive results.[7]
- Low-positive MOG-IgG results require particular caution and interpretation with the complete diagnostic criteria.[6][2]
Cerebrospinal fluid analysis
- Neuromyelitis optica spectrum disorder CSF analysis supports diagnosis and exclusion of mimics; it is recommended, although not mandatory.[4]
- Basic studies: CSF white and red cell counts, differential, protein, lactate, oligoclonal bands, and paired CSF/serum glucose.[4]
- Pleocytosis: Increased CSF white blood cells may occur, including neutrophils or eosinophils. These findings do not independently distinguish NMOSD from infection.[2]
- Oligoclonal bands: CSF-restricted bands are absent in most patients. Their presence does not independently exclude NMOSD.[2]
- Paired specimens: Compare CSF with serum collected at the same time. Oligoclonal bands are assessed by isoelectric focusing; distinguish bands restricted to CSF from those shared with serum.[8]
- Protein and albumin quotient: CSF protein and the CSF/serum albumin quotient may increase. Interpret the quotient against age-related laboratory reference limits.[4][8]
- Intrathecal immunoglobulins: Paired CSF/serum immunoglobulin measurements interpreted with albumin-adjusted quotient diagrams help assess intrathecal synthesis. An isolated immunoglobulin G index has limited specificity when blood-CSF barrier dysfunction is substantial.[8][4]
- Lactate and glucose: Lactate may rise during attacks. Glucose must be interpreted with the paired serum value; these measurements also help evaluate alternative causes such as infection.[4][8]
- Normal results: Normal CSF, especially during isolated optic neuritis, does not exclude NMOSD.[4]
Measles-rubella-varicella-zoster reaction
- Neuromyelitis optica spectrum disorder usually has a negative measles, rubella, and varicella-zoster virus (MRZ) reaction. This specialized test assesses a polyspecific intrathecal antibody response; positivity involving at least two of these viruses favors multiple sclerosis. A negative result does not establish NMOSD.[4]
Additional laboratory investigations
- Neuromyelitis optica spectrum disorder evaluation may include blood count, biochemistry, coagulation, urinalysis, and autoimmune serology.[4]
- Autoimmune tests include antinuclear antibodies, extractable nuclear antigen antibodies, antibodies to double-stranded deoxyribonucleic acid (DNA), antineutrophil cytoplasmic antibodies, and anticardiolipin antibodies.[4]
- Select nutritional, metabolic, infectious, and paraneoplastic investigations according to the presentation. These are directed investigations rather than an identical mandatory panel for every patient.[4]
Interpretation of antibody titers
- Neuromyelitis optica spectrum disorder follow-up should not rely on AQP4-IgG titers to predict attacks. A subsequent negative result does not by itself establish absence of relapse risk.[9]
Laboratory safety monitoring
- Neuromyelitis optica spectrum disorder laboratory monitoring during immunotherapy depends on the treatment used and the patient's risk factors.[9]
- Relevant measurements may include complete blood count with differential, liver enzymes, serum immunoglobulins, and peripheral B-cell counts, according to the regimen.[9]
- Hepatitis B screening is important before B-cell-depleting therapies. Additional infection screening is selected according to the planned treatment and clinical context.[9]
- These tests help detect treatment-related cytopenias, liver toxicity, and reduced immunoglobulin concentrations; they do not independently diagnose NMOSD.[9]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729. PMID: 26092914.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Yamout B, Gouider R, Al-Roughani R, et al. Consensus recommendations for the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD): The MENACTRIMS guidelines. CNS Drugs. 2026;40(3):283-303. doi:10.1007/s40263-025-01260-x. PMID: 41591715.
- ↑ Franciotta D, Gastaldi M, Sala A, et al. Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurological Sciences. 2017;38(Suppl 2):231-236. doi:10.1007/s10072-017-3027-1. PMID: 29030768.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology. 2023;270(7):3341-3368. doi:10.1007/s00415-023-11634-0. PMID: 37022481.
- ↑ Giorgi L, Marignier R, Pique J, et al.; MIRCEM network. French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder. Revue Neurologique (Paris). Published online July 21, 2026. doi:10.1016/j.neurol.2026.06.004. PMID: 42481362.
- ↑ 6.0 6.1 Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8. PMID: 36706773.
- ↑ Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Journal of Neuroinflammation. 2018;15:134. doi:10.1186/s12974-018-1144-2. PMID: 29724224.
- ↑ 8.0 8.1 8.2 8.3 Tumani H, Petereit HF, Gerritzen A, et al. S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version). Neurological Research and Practice. 2020;2:8. doi:10.1186/s42466-020-0051-z. PMID: 33324914.
- ↑ 9.0 9.1 9.2 9.3 9.4 Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271:141-176. Published online September 7, 2023. doi:10.1007/s00415-023-11910-z. PMID: 37676297.